Schizophrenia Clinical Trial
Official title:
An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Verified date | June 2024 |
Source | Karuna Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily [BID]) in subjects with schizophrenia.
Status | Enrolling by invitation |
Enrollment | 280 |
Est. completion date | February 28, 2026 |
Est. primary completion date | February 28, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 59 Years |
Eligibility | Inclusion Criteria: 1. Subject is aged =18 to <60 years at the time of randomization of Study KAR-012 2. Subject has successfully completed the treatment period of Study KAR-012 3. Subject has been compliant with the procedures in Study KAR-012 (in the Investigator's judgement) 4. Subject has been compliant with their background antipsychotic drug in Study KAR-012 in the opinion of the Investigator and based on subject and informant reporting Note: Subjects are required to remain on the same appropriate approved APD as in Study KAR-012 and should stay on that same dose throughout the study. 5. Subject is capable of providing signed Informed Consent Form before any study assessments will be performed 6. Subject resides in a stable living situation, in the opinion of the Investigator 7. Subject has identified a reliable informant/caregiver willing and able to assist with study activities as needed throughout the subject's participation in the study. The informant can complete the study visits assessments via phone (as per local regulations). In Bulgaria, the informant needs to be physically present at all study visits where the Investigator determines that his/her input would be beneficial. 8. Women of childbearing potential (WOCP), or men whose sexual partners are WOCP, must be able and willing to use at least 1 highly effective method of contraception during the study and for at least 1 menstrual cycle (e.g., 30 days) after the last dose of study drug. Sperm donation is not allowed for 30 days after the final dose of the study drug. A female subject is considered to be a WOCP after menarche and until she is in a postmenopausal state for 12 months or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, or bilateral oophorectomy). Exclusion Criteria: 1. Risk for suicidal behavior during the study as determined by the Investigator's clinical assessment and/or Columbia-Suicide Severity Rating Scale (C-SSRS) as confirmed by the following: 1. Subject answers "Yes" to "suicidal ideation" Item 4 (active suicidal ideation with some intent to act, without a specific plan) or Item 5 (active suicidal ideation with a specific plan and intent) on the C-SSRS 2. Non-suicidal self-injurious behavior is not exclusionary 2. Any clinically significant abnormalities, including any finding(s) from ECG, or laboratory test at Visit 6, and the physical examination, vital signs, at the EOT visit of Study KAR-012 that the Investigator, in consultation with the Medical Monitor are considered to jeopardize the safety of the subject 3. Female subject is pregnant 4. If, in the opinion of the Investigator (and/or Sponsor/ Medical Monitor), subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the Investigator (and/or Sponsor /Medical Monitor), may compromise the safety of the subject or affect their ability to adhere to the protocol visit schedule or study requirements 5. Risk of violent or destructive behavior as per Investigator's judgement 6. Subjects participating in another investigational drug or device trial or planning on participating in another clinical trial during the study 7. History or high risk of urinary retention, gastric retention, or narrow angle glaucoma as evaluated by the Investigator 8. Subject is taking, or plans to take while in the study, any prohibited concomitant medication 9. For all male subjects only, any one of the following: 1. History of bladder stones 2. History of recurrent urinary tract infections 3. Serum prostate specific antigen (PSA) >10 ng/mL 4. An International Prostate Symptom Score (IPSS) of 5 (almost always) on either item 1, 3, 5, or 6 5. A sum of scores on IPSS items 1, 3, 5, and 6 of =9 Note: IPSS will be required only for male subjects = 45 years of age. Subjects already enrolled in the study who do not have available PSA values from Study KAR-012 for baseline value use in Study CN012-0009, will have these assessments at their next clinic visit planned after re-consenting to determine current eligibility. |
Country | Name | City | State |
---|---|---|---|
Bulgaria | Local Institution - 318 | Cherven Bryag | |
Bulgaria | Local Institution - 311 | Dupnitsa | |
Bulgaria | Local Institution - 316 | Kardzhali | |
Bulgaria | Local Institution - 302 | Kazanlak | |
Bulgaria | Local Institution - 304 | Novi Iskar | |
Bulgaria | Local Institution - 301 | Pleven | |
Bulgaria | UMHAT 'Dr. Georgi Stranski', EAD | Pleven | |
Bulgaria | Local Institution - 314 | Plovdiv | |
Bulgaria | Local Institution - 321 | Plovdiv | |
Bulgaria | Local Institution - 313 | Razgrad | |
Bulgaria | MHAT Dr Ivan Seliminski AD | Sliven | |
Bulgaria | Local Institution - 303 | Sofia | |
Bulgaria | Local Institution - 305 | Sofia | |
Bulgaria | Local Institution - 306 | Sofia | |
Bulgaria | Local Institution - 307 | Sofia | |
Bulgaria | Local Institution - 309 | Sofia | |
Bulgaria | Local Institution - 320 | Sofia | |
Bulgaria | Local Institution - 317 | Targovishte | |
Bulgaria | DCC Mladost M - Varna, OOD | Varna | |
Bulgaria | Local Institution - 310 | Vratsa | |
India | Local Institution - 604 | Ahmedabad | Gujarat |
India | Local Institution - 607 | Ahmedabad | Gujarat |
India | Local Institution - 615 | Ajmer | Rajasthan |
India | Local Institution - 610 | Aurangabad | Maharashtra |
India | Local Institution - 617 | Belgavi | Karnataka |
India | Local Institution - 616 | Guwahati | Assam |
India | Local Institution - 611 | Kozhikode | Kerala |
India | Local Institution - 612 | Lucknow | Uttar Pradesh |
India | Local Institution - 602 | Mangalore | Karnataka |
India | Local Institution - 614 | Mangalore | Karnataka |
India | Local Institution - 601 | Mysore | Karnataka |
India | Local Institution - 603 | Nagpur | Maharashtra |
India | Local Institution - 605 | Nashik | Maharashtra |
India | Local Institution - 608 | Nashik | Maharashtra |
India | Local Institution - 606 | Rajkot | Rajasthan |
India | Local Institution - 609 | Surat | Gujarat |
India | Local Institution - 613 | Vadodara | Gujarat |
Poland | Local Institution - 506 | Bialystok | |
Poland | Local Institution - 507 | Gdansk | |
Poland | Local Institution - 509 | Grudziadz | |
Poland | Local Institution - 501 | Kielce | |
Poland | Local Institution - 503 | Lodz | |
Poland | Local Institution - 505 | Lublin | |
Poland | Local Institution - 502 | Siemianowice Slaskie | |
Poland | Local Institution - 508 | Suchy Las | |
Poland | Local Institution - 504 | Tuszyn | |
Romania | Local Institution - 803 | Brasov | |
Romania | Local Institution - 802 | Bucuresti | |
Romania | Local Institution - 804 | Bucuresti | |
Romania | Local Institution - 807 | Bucuresti | |
Romania | Local Institution - 809 | Bucuresti | |
Romania | Local Institution - 810 | Bucuresti | |
Romania | Local Institution - 808 | Craiova | |
Romania | Local Institution - 801 | Galati | |
Romania | Local Institution - 806 | Iasi | |
Romania | Local Institution - 805 | Sibiu | |
Serbia | Local Institution - 402 | Belgrade | |
Serbia | Local Institution - 403 | Belgrade | |
Serbia | Local Institution - 405 | Belgrade | |
Serbia | Local Institution - 413 | Belgrade | |
Serbia | Local Institution - 417 | Belgrade | |
Serbia | Local Institution - 404 | Kovin | |
Serbia | Local Institution - 414 | Kovin | |
Serbia | Local Institution - 401 | Kragujevac | |
Serbia | Local Institution - 406 | Kragujevac | |
Serbia | Local Institution - 408 | Kragujevac | |
Serbia | University Clinical Center Kragujevac | Kragujevac | |
Serbia | Local Institution - 411 | Nis | |
Serbia | Local Institution - 415 | Nis | |
Serbia | Local Institution - 410 | Novi Knezevac | |
Serbia | Local Institution - 416 | Novi Knezevac | |
Serbia | Local Institution - 409 | Vrsac | |
United Kingdom | Local Institution - 706 | Ashton Under Lyne | Lancashire |
United Kingdom | Local Institution - 703 | Birmingham | West Midlands |
United Kingdom | Local Institution - 707 | Bodmin | Cornwall |
United Kingdom | Local Institution - 705 | Brighton | East Sussex |
United Kingdom | Local Institution - 702 | Chertsey | Surrey |
United Kingdom | Local Institution - 701 | London | Greater London |
United Kingdom | Local Institution - 708 | Oxford | Oxfordshire |
United Kingdom | Local Institution - 704 | Paisley | Renfrewshire |
United States | Advanced Research Center, Inc. | Anaheim | California |
United States | Local Institution - 184 | Ann Arbor | Michigan |
United States | Grady Memorial Hospital | Atlanta | Georgia |
United States | Synexus Clinical Research US, Inc. | Atlanta | Georgia |
United States | Local Institution - 135 | Augusta | Georgia |
United States | Community Clinical Research, Inc. | Austin | Texas |
United States | Local Institution - 163 | Beachwood | Ohio |
United States | Northwest Clinical Research Center | Bellevue | Washington |
United States | CITrials - Bellflower | Bellflower | California |
United States | Local Institution - 158 | Boston | Massachusetts |
United States | Local Institution - 187 | Boston | Massachusetts |
United States | Synexus Clinical Research US, Inc. | Cerritos | California |
United States | Local Institution - 142 | Chicago | Illinois |
United States | Local Institution - 177 | Chicago | Illinois |
United States | Uptown Research Institute, LLC | Chicago | Illinois |
United States | Local Institution - 165 | Cincinnati | Ohio |
United States | Local Institution - 186 | Coral Gables | Florida |
United States | Local Institution - 167 | Culver City | California |
United States | CenExel iResearch Atlanta | Decatur | Georgia |
United States | Local Institution - 141 | Encino | California |
United States | Local Institution - 179 | Eugene | Oregon |
United States | Local Institution - 166 | Gaithersburg | Maryland |
United States | Local Institution - 168 | Garfield Heights | Ohio |
United States | Local Institution - 149 | Grand Rapids | Michigan |
United States | Galiz Research, LLC | Hialeah | Florida |
United States | Local Institution - 182 | Hialeah | Florida |
United States | Local Institution - 176 | Hickory | North Carolina |
United States | Local Institution - 180 | Houston | Texas |
United States | Local Institution - 183 | Houston | Texas |
United States | University Hills Clinical Research - Irving | Irving | Texas |
United States | Local Institution - 162 | Kalamazoo | Michigan |
United States | Local Institution - 152 | La Habra | California |
United States | Sunwise Clinical Research, LLC. | Lafayette | California |
United States | Altea Research Institute, Las Vegas | Las Vegas | Nevada |
United States | Local Institution - 147 | Las Vegas | Nevada |
United States | Synergy Clinical Research of Escondido | Lemon Grove | California |
United States | Local Institution - 175 | Little Rock | Arkansas |
United States | Woodland International Research Group, LLC | Little Rock | Arkansas |
United States | CenExel Collaborative Neuroscience Research | Los Alamitos | California |
United States | Local Institution - 169 | Marietta | Georgia |
United States | Local Institution - 105 | Miami | Florida |
United States | Local Institution - 120 | Miami | Florida |
United States | Premier Clinical Research Institute, Inc. | Miami | Florida |
United States | Assertive Research Center | Miami Lakes | Florida |
United States | Local Institution - 173 | Miami Lakes | Florida |
United States | Local Institution - 171 | Miami Springs | Florida |
United States | Local Institution - 154 | Monroe | Louisiana |
United States | Local Institution - 104 | New York | New York |
United States | Local Institution - 157 | New York | New York |
United States | Local Institution - 160 | New York | New York |
United States | Local Institution - 181 | Oceanside | California |
United States | Local Institution - 174 | Omaha | Nebraska |
United States | NRC Research Institute | Orange | California |
United States | Local Institution - 124 | Orange City | Florida |
United States | Local Institution - 139 | Overland Park | Kansas |
United States | Local Institution - 156 | Pembroke Pines | Florida |
United States | Local Institution - 161 | Phoenix | Arizona |
United States | CNRI - Los Angeles, LLC | Pico Rivera | California |
United States | Pillar Clinical Research, LLC | Richardson | Texas |
United States | At Health Texas | Richmond | Texas |
United States | CITrials, Inc. - Riverside & San Bernardino County | Riverside | California |
United States | Psychiatry and Alzheimer's Care of Rochester. PLLC | Rochester | New York |
United States | Green Mountain Research Institute | Rutland | Vermont |
United States | Local Institution - 178 | Saint Louis | Missouri |
United States | PsychCare Consultants Research | Saint Louis | Missouri |
United States | Local Institution - 164 | Stanford | California |
United States | Richmond Behavioral Associates ERG Clinical Research - New York PLLC | Staten Island | New York |
United States | Interventional Psychiatry of Tampa Bay | Tampa | Florida |
United States | CenExel Collaborative Neuroscience Research | Torrance | California |
United States | Local Institution - 185 | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Karuna Therapeutics |
United States, Bulgaria, India, Poland, Romania, Serbia, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of treatment-emergent adverse events (TEAEs) | From initial dose to safety follow-up visit (54 weeks) or early termination | ||
Secondary | Incidence of serious treatment-emergent adverse events (TEAEs) | From initial dose to safety follow-up visit (54 weeks) or early termination | ||
Secondary | Incidence of TEAEs leading to discontinuation of study drug | From initial dose to safety follow-up visit (54 weeks) or early termination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |